CTSZ and neurodegenerative disease: Thus, a new generation of selective and reversible cathepsin X inhibitors (Fonovic et al., 2017) may be expected to significantly improve the cathepsin X-targeted therapy of neurodegenerative diseases related with neuroinflammation.